Replies to post #4698 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>the conundrum is that patients with DIC are at risk of both clotting and bleeding. The clotting results in a consumptive coagulopathy which then predisposes to hemorrhage<

rFVIIa is sometimes given when this happens, but that’s not a market I’d expect GTC to pursue, for obvious reasons :-)